Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | STK-009 |
| Synonyms | |
| Therapy Description |
STK-009 is an IL-2 mutein that stimulates a modified form of IL-2 receptor beta (IL-2R beta) while not stimulating wild-type IL-2R beta, potentially leading to enhanced antitumor response in combination with CAR T cells expressing the modified IL-2R beta (Cancer Res (2022) 82 (12_Supplement): 2824). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| STK-009 | STK009|STK009 | STK-009 is an IL-2 mutein that stimulates a modified form of IL-2 receptor beta (IL-2R beta) while not stimulating wild-type IL-2R beta, potentially leading to enhanced antitumor response in combination with CAR T cells expressing the modified IL-2R beta (Cancer Res (2022) 82 (12_Supplement): 2824). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|